Month: June 2026

Introduction and Objective: Type 1 diabetes (T1D) is driven by loss of immune tolerance and immune-mediated destruction of functional β cells. Effective therapies should preserve and regenerate β cells while reducing immunogenicity and restoring immune regulation. Harmine (H) plus exendin-4 (E) robustly expands human β cells, but its impact on β cell survival and immunogenicity […]

Introduction and Objective: Inflammatory cytokine signaling contributes to beta-cell autoimmunity in type 1 diabetes (T1D), but the contribution of interferon-gamma (IFNγ) versus other inflammatory pathways remains unclear. We hypothesized that beta-cells from donors with T1D display elevated IFNγ response relevant to autoimmunity.Methods: We identified differentially expressed genes from two publicly available human islet bulk RNA-seq […]

Introduction and Objective: Lifestyle interventions are the foundation of prediabetes (pre-DM) and type 2 diabetes (T2D) management. High levels of food insecurity hinder the ability to create healthy eating habits. Prospective food is medicine intervention studies have not been conducted in pediatric T2D populations to date. This ongoing prospective study evaluates the efficacy of a […]

Introduction and Objective: In patients undergoing total pancreatectomy (TP), adequate glycemic control is a major concern. Previously, a 7-day treatment with a bihormonal artificial pancreas (BIHAP), delivering both insulin and glucagon for fully closed-loop regulation, improved glycemic control. However, evidence on its long-term efficacy is lacking.Methods: This randomised open-label crossover trial compared BIHAP treatment with […]

Introduction and Objective: Gestational Diabetes Mellitus (GDM) screening at 24-28 weeks limits early intervention. Emerging studies, such as GLAM, have evaluated early screening using Continuous Glucose Monitoring (CGM) and standard metrics (e.g., TA140) as biomarkers, showing promising results. We hypothesize that novel features derived from post-prandial (PP) glucose profiles can outperform standard CGM metrics and […]

Introduction and Objective: Carbohydrate counting is perceived as one of the most burdensome tasks in Type 1 Diabetes (T1D) but meta-analyses have shown it is an effective method in reducing HbA1c. We compared glycemic control in adults with T1D using mylife YpsoPump with advanced hybrid closed loop (HCL) system (mylife CamAPS FX app) among those […]

Introduction and Objective: Enlicitide is an oral PCSK9 inhibitor that, in two Phase 3 randomized, placebo-controlled trials, demonstrated LDL-C reduction of approximately 60% and was well tolerated. Here we report the efficacy of enlicitide in participants with and without diabetes mellitus (DM) at baseline, and the incidence of new onset or worsening diabetes.Methods: CORALreef Lipids […]

Introduction and Objective: To evaluate the efficacy and safety of mazdutide 6 mg vs semaglutide 1 mg in Chinese T2D patients (pts) with obesity who had inadequately glycaemic control and suboptimal weight loss (WL) following lifestyle interventions with or without metformin (NCT06184568).Methods: A total of 349 pts aged ≥18 years with T2D duration ≤10 years […]

Introduction and Objective: Heart Failure (HF) in T2D is common and increases mortality. IV Ketone infusion improves EF% ~6% at 3hrs in patients with T2D and HFrEF. Oral ketones (OKE) have shown similar results. Here, we evaluate the effect of chronic OKE administration (7 days) on cardiac efficiency.Methods: 12 subjects with T2D and HFrEF underwent […]

Introduction and Objective: CGM uptake remains limited in insulin-using older population in spite of data showing its effectiveness in improving glycemic control and lowering hypoglycemia risk. Whether remote education with strategies to overcome age-related barriers can improve adoption of CGM in older population is not known.Methods: In this prospective 6-month intervention study, we enrolled older […]